Diabetes Technology Starts: Amir Hayeri From BioConscious On Using AI To Predict Glucose And Flag Risk
Failed to add items
Add to basket failed.
Add to wishlist failed.
Remove from wishlist failed.
Adding to library failed
Follow podcast failed
Unfollow podcast failed
Diabetes Technology Starts: Amir Hayeri From BioConscious On Using AI To Predict Glucose And Flag Risk
-
Narrated by:
-
By:
We talk with Amir Hayeri, founder and CEO of BioConscious Technologies, about using machine learning to predict glucose trends and turn CGM streams into actionable clinical foresight. We dig into accuracy, trust, liability, and why clustering dysglycemia may reveal risk that HbA1c can miss.
• Amir’s origin story and the prevention-first philosophy behind BioConscious
• Predicting glucose 60 minutes ahead using CGM data and how accuracy is measured
• Why an app without a clinical workflow has limited impact
• Population triage for clinics using clustering to surface high-risk patients fast
• Clinician concerns about liability and the fear of replacing doctors
• Building trust through explainable AI and a clear user interface
• Plans for studies and publication areas including gestational diabetes and dysglycemia
• The “glucose atlas” idea and what CGM can show in non-diabetic users
• Limits of mixing CGM with wearables data and why model complexity can hurt performance